Interestingly we have also noted a similar loss in anti-HER3 CD4+ Th1 in TNBC and ERpos breast cancer suggesting similar loses of anti-oncodriver Th1 may be a common theme in several breast cancer subtypes and replacing Th1 cytokines may be a critical component in breast cancer therapy in general. Here, CD4 is linked to breast carcinoma.